Tau ASO Therapy

Tau ASO Therapy

Overview

Tau antisense oligonucleotide (ASO) therapy represents a gene-silencing approach for treating Alzheimer's disease and other tauopathies. Unlike antibody-based immunotherapies that clear tau after it's produced, ASOs prevent tau production at the source by degrading MAPT messenger RNA (mRNA)[@tau][@biib2022]. This approach offers a fundamentally different mechanism with potential for disease modification.

Mechanism of Action

Tau ASO therapy works through RNA interference at the molecular level[@tau][@biib2022]:

1. ASO Design and Target Selection

• Target: MAPT mRNA (the messenger RNA encoding the tau protein)
• Sequence: ASO is designed to be complementary to a specific region of MAPT mRNA
• Chemistry: Modified ASOs with phosphorothioate backbone for enhanced stability and CNS delivery

2. RNase H1-Mediated mRNA Degradation

Once the ASO binds to its target mRNA[@biib2022]:

• Hybrid Formation: ASO forms a duplex with target mRNA
• RNase H1 Recruitment: The DNA-RNA hybrid recruits RNase H1 enzyme
• mRNA Cleavage: RNase H1 cleaves the RNA strand within the hybrid
• Degradation: The cleaved mRNA fragments are degraded by cellular exonucleases
• Translation Block: Without intact mRNA, ribosomes cannot produce tau protein

...

Tau ASO Therapy

Overview

Tau antisense oligonucleotide (ASO) therapy represents a gene-silencing approach for treating Alzheimer's disease and other tauopathies. Unlike antibody-based immunotherapies that clear tau after it's produced, ASOs prevent tau production at the source by degrading MAPT messenger RNA (mRNA)[@tau][@biib2022]. This approach offers a fundamentally different mechanism with potential for disease modification.

Mechanism of Action

Tau ASO therapy works through RNA interference at the molecular level[@tau][@biib2022]:

1. ASO Design and Target Selection

• Target: MAPT mRNA (the messenger RNA encoding the tau protein)
• Sequence: ASO is designed to be complementary to a specific region of MAPT mRNA
• Chemistry: Modified ASOs with phosphorothioate backbone for enhanced stability and CNS delivery

2. RNase H1-Mediated mRNA Degradation

Once the ASO binds to its target mRNA[@biib2022]:

• Hybrid Formation: ASO forms a duplex with target mRNA
• RNase H1 Recruitment: The DNA-RNA hybrid recruits RNase H1 enzyme
• mRNA Cleavage: RNase H1 cleaves the RNA strand within the hybrid
• Degradation: The cleaved mRNA fragments are degraded by cellular exonucleases
• Translation Block: Without intact mRNA, ribosomes cannot produce tau protein

3. Reduction in Tau Protein Production

The result is a coordinated reduction in[@tau][@biib2022]:

• Total Tau: All tau isoforms produced from MAPT gene
• Phospho-tau: Pathologically phosphorylated tau species
• Tau Aggregates: Reduced substrate for aggregate formation
• Tau Spread: Lower levels available for propagation

Clinical Evidence

BIIB080 (MAPTRx) - Phase I/II Results

The most advanced tau ASO, BIIB080 (developed by Biogen and Ionis), has demonstrated compelling results[@biib][@biiba]:

Phase I Trial (NCT03119818):

• Dose-dependent reduction in CSF total tau (up to 50-60%)
• Dose-dependent reduction in CSF phospho-tau species
• Acceptable safety profile
• Results published in Nature Medicine (2022)

Phase I/II Trial (NCT04784160):

• Sustained tau reduction over extended treatment
• Validated the ASO approach in AD patients
• Results published in JAMA Neurology (2023)

Phase II Trial (NCT05399888):

• Active for early Alzheimer's disease
• Further evaluation of cognitive endpoints

NIO752 - Phase I Results

NIO752 is another tau ASO developed by Roche/Ionis for PSP and AD[@nio]:

• Target: MAPT mRNA
• Results: Demonstrated target engagement in Phase I
• Status: Phase I completed for PSP

Advantages Over Antibody Therapy

Tau ASO therapy offers several potential advantages[@tau][@biib2022]:

| Feature | ASO Therapy | Antibody Therapy |
|---------|-------------|-------------------|
| Mechanism | Prevents tau production | Clears existing tau |
| Target | mRNA (source) | Protein (product) |
| Distribution | CNS-wide after intrathecal | Limited by BBB |
| Isoform Coverage | All isoforms | Depends on epitope |
| Dosing Frequency | Monthly to quarterly | Monthly |

Disease-Modifying Potential

ASOs address the root cause of tau pathology:

• Prevention: Stops new tau production before aggregates form
• Reduction: Lowers overall tau burden
• Combination Potential: Could be combined with amyloid clears

Challenges and Limitations

Delivery Challenges

• Intrathecal Administration: Requires lumbar puncture for CNS delivery
• Distribution: May not reach all brain regions uniformly
• Patient Burden: More invasive than intravenous antibody infusion

Safety Considerations

• Off-Target Effects: ASOs may affect unintended RNAs
• Long-Term Safety: Unknown effects of chronic tau reduction
• Target Engagement: Requires demonstration of CSF tau lowering

Clinical Development

• Patient Selection: Optimal patient population unclear
• Biomarker Correlation: CSF tau reduction may not predict clinical benefit
• Trial Design: Long trials needed for disease modification endpoints

Comparison of Tau ASO Programs

| Drug | Company | Target | Phase | Key Results |
|------|---------|--------|-------|--------------|
| BIIB080 | Biogen/Ionis | MAPT mRNA | Phase II | 50-60% CSF tau reduction |
| NIO752 | Roche/Ionis | MAPT mRNA | Phase I | Target engagement demonstrated |
| ARO-MAPT | Arrowhead | MAPT mRNA (RNAi) | Preclinical | Preclinical proof-of-concept |

Future Directions

Tau ASO therapy continues to evolve[@tau]:

Improved Delivery: Exploring convection-enhanced delivery and AAV vectors

Oral ASOs: Next-generation ASOs with oral bioavailability

Combination Therapy: ASO + amyloid antibody combinations

Biomarker Integration: Using plasma p-tau for patient selection

Gene Therapy: AAV-delivered shRNA for long-term tau reduction

Tau Isoform-Specific ASO Targeting

The MAPT gene produces six tau isoforms through alternative splicing, and ASO design can be tailored to target specific isoforms[@tauisoforms2024]. This isoform-specific targeting represents a sophisticated approach to treating different tauopathies.

Tau Isoform Biology

The six tau isoforms arise from alternative splicing of exons 2, 3, and 10 in the MAPT gene:

• 3-repeat (3R) tau: Exon 10 excluded (exon 2 and 3 may be included or excluded)
• 4-repeat (4R) tau: Exon 10 included (exon 2 and 3 may be included or excluded)

| Isoform | Exon 2 | Exon 3 | Exon 10 | Repeats | Length (aa) |
|---------|--------|--------|---------|---------|-------------|
| 0N3R | - | - | - | 3 | 352 |
| 1N3R | + | - | - | 3 | 379 |
| 2N3R | + | + | - | 3 | 410 |
| 0N4R | - | - | + | 4 | 383 |
| 1N4R | + | - | + | 4 | 410 |
| 2N4R | + | + | + | 4 | 441 |

Isoform Targeting Strategies

1. Total MAPT Knockdown:

• Targets all six tau isoforms
• Maximum tau reduction (50-60% observed with BIIB080)
• Concerns about tau loss-of-function effects on microtubule function
• Non-human primate studies support safety at therapeutic doses

2. 4R-Selective Targeting:

• 4R tau isoforms are elevated in PSP, CBD, and other 4R-tauopathies
• ASOs can be designed to preferentially reduce 4R isoforms by targeting exon 10
• May preserve 3R tau function for normal neuronal physiology
• Particularly relevant for pure tauopathies without amyloid co-pathology

3. Exon-Specific Targeting:

• Exon 10 splicing produces 4R tau (3 repeats vs 4 repeats)
• ASOs can modulate exon 10 inclusion by targeting splicing regulatory elements
• Therapeutic potential for 4R-tauopathies like PSP and CBD
• Requires careful design to avoid off-target splicing effects

Clinical Implications

• BIIB080 reduces total tau (all isoforms) — suitable for AD where both 3R and 4R are pathological
• Isoform-selective ASOs in development for specific tauopathies (PSP, CBD)
• Need to balance efficacy with safety — partial reduction may be optimal
• Biomarker development to monitor isoform-specific effects (CSF 3R/4R tau assays)

Safety and Long-Term Effects

Tau Reduction Concerns

Tau is essential for microtubule stabilization in neurons, raising concerns about complete knockout[@tau][@biib2022]:

• Physiological Function: Tau binds to microtubules and promotes their assembly
• Axonal Transport: Tau facilitates vesicle transport along microtubules
• Synaptic Function: Tau is involved in synaptic plasticity
• Complete Knockout: Mouse tau knockout shows minimal phenotype, but human data limited

Key Finding: ASOs achieve partial reduction (50-60%), not complete knockout, which may be sufficient for therapeutic benefit while preserving essential functions.

Non-Human Primate Studies

Preclinical toxicology in non-human primates supports the safety of tau ASOs:

• Dose-Range Findings: No significant adverse effects at therapeutic doses
• Tau Reduction: Demonstrated dose-dependent CSF tau lowering
• Motor Function: No observable deficits in primate studies
• Histopathology: No relevant CNS pathology at dose levels

Clinical Safety Data

From BIIB080 Phase I and I/II trials[@biib][@biiba]:

• Injection Site Reactions: Occurred in some patients (IT administration)
• CSF Protein: Transient elevation in some participants
• Neuroinflammation: No significant increase in inflammatory markers
• Liver Enzymes: Mild elevations, reversible upon discontinuation
• AEs Leading to Discontinuation: Low rate (<5%)

Long-Term Considerations

• Chronic Dosing: Monthly dosing for up to 12 months showed acceptable safety
• Tau Recovery: Upon discontinuation, CSF tau levels return to baseline
• Immune Response: No anti-drug antibodies detected
• Cognitive Effects: No negative cognitive outcomes in treated patients

Preclinical Validation Models

Animal Models Used for Tau ASO Development

Tau ASO development leveraged multiple preclinical models:

Transgenic Mouse Models:

• P301S mice: Express human mutant tau (P301S), develop NFT pathology
• rTg4518 mice: Inducible mutant tau expression, rapid progression
• MAPT knockout mice: For safety assessment of tau reduction

Key Findings:

• ASO treatment reduced CSF and brain tau by 40-80%
• Improved behavioral outcomes in some studies
• Reduced tau pathology markers (AT8, AT100, Gallyas)
• No adverse effects on motor function at therapeutic doses

Biomarker Translation

Translating preclinical biomarker findings to clinical setting:

| Preclinical Marker | Clinical Correlate | Status |
|-------------------|-------------------|--------|
| Brain tau (IHC) | Tau PET | Validated |
| CSF total tau | CSF t-tau | Validated |
| CSF p-tau181/217 | CSF p-tau181/217 | Validated |
| Brain AT8 signal | CSF p-tau | Partial |
| Motor behavior | Clinical exams | Variable |

ASO Chemistry and Delivery

Chemical Modifications

Modern ASOs employ sophisticated chemistry for CNS delivery[@asochemistry2024]:

Phosphorothioate (PS) Backbone:

• Replaces non-bridging oxygen with sulfur
• Enhances nuclease resistance
• Improves protein binding (cellular uptake)

2'-O-Methyl (2'-OMe) or 2'-O-Methoxyethyl (2'-MOE):

• 2'-ribose modifications
• Enhanced affinity for target RNA
• Reduced immunostimulation

Locked Nucleic Acid (LNA):

• Constrained nucleotide structure
• High binding affinity
• Improved specificity

Gapmer Design:

• Central DNA "gap" flanked by modified nucleotides
• Optimizes RNase H1 recruitment
• Balances stability and activity

Delivery to the CNS

Intrathecal (IT) Administration:

• Lumbar puncture delivery to cerebrospinal fluid
• BIIB080 uses this route
• Bypasses BBB for CNS exposure

Convection-Enhanced Delivery (CED):

• Direct brain infusion under pressure
• Better distribution than IT
• Being explored for next-generation ASOs

AAV-Mediated shRNA:

• AAV vectors deliver shRNA expression cassettes
• Long-term tau reduction from single dose
• Preclinical development

Distribution Kinetics

| Parameter | Intrathecal | IV | AAV |
|-----------|-------------|-----|-----|
| CNS Exposure | High | Low | High |
| Onset | Weeks | N/A | Months |
| Duration | Months | N/A | Years |
| Patient Burden | Moderate | Low | Low |

RNase H1 Mechanism Deep Dive

RNase H1 is critical for ASO-mediated mRNA degradation[@rnaseh12023]:

Structure and Function

• RNase H1 recognizes DNA-RNA hybrids
• Cleaves the RNA strand endonucleolytically
• Requires a minimum 5-nucleotide DNA "gap" in the hybrid
• Expressed in CNS neurons and glia

ASO Design Optimization

Gapmer Length: 5-10 nucleotides optimal

Positioning: Central DNA region for RNase H1 binding

Flanking: 2'-modified nucleotides for stability

Sequence: Target conserved regions of MAPT mRNA

Off-Target Considerations

• RNase H1 may cleave unintended RNA pairs
• Computational design reduces off-target risk
• Chemical modifications improve specificity

Comparison: ASO vs Antibody vs Small Molecule

| Feature | ASO (BIIB080) | Antibody (E2814) | Small Molecule (LY3372689) |
|---------|---------------|------------------|----------------------------|
| Target | MAPT mRNA | Tau protein | O-GlcNAc hydrolase |
| Mechanism | Reduce production | Clear existing | Increase O-GlcNAcylation |
| Route | Intrathecal | IV | Oral |
| Dosing | Monthly | Monthly | Daily |
| Distribution | CNS-wide | Limited by BBB | CNS-penetrant |
| Isoform Selectivity | All isoforms | Epitope-dependent | All isoforms |
| Phase | Phase II | Phase III | Phase II |

Clinical Trial Design Considerations

Patient Selection

• Early AD (MCI or mild dementia)
• Elevated tau markers (PET or CSF)
• Genetic forms (PSEN1, PSEN2, APP) for DIAN-TU

Endpoints

Primary:

• Safety and tolerability
• CSF total tau and p-tau

Secondary:

• Cognitive measures (CDR-SB, ADAS-Cog)
• Tau PET imaging
• Plasma biomarkers

Biomarker Correlations

• CSF tau reduction correlates with target engagement
• May predict clinical outcomes
• Surrogate endpoint for disease modification

Future Directions in Tau Gene Therapy

Next-Generation Approaches

RNAi-Based Therapies:

• siRNA and shRNA approaches
• AAV-delivered gene silencing

CRISPR-Based Editing:

• Inactivate MAPT gene
• Allele-specific targeting (for mutations)

Small Molecule Splicing Modulators:

• Modulate exon 10 splicing
• Reduce 4R tau selectively

Combination Strategies

• ASO + amyloid antibody (e.g., lecanemab)
• ASO + tau antibody
• ASO + OGA inhibitor

This approach represents a complementary strategy to antibody-based immunotherapy, targeting tau at its source rather than clearing already-produced protein.

References

Unknown, Tau ASO therapy review (n.d.)

[Unknown, BIIB080 mechanism of action (2022)](https://doi.org/10.1016/j.natmed.2022.09.018)

[Unknown, BIIB080 Phase 1 results (n.d.)](https://pubmed.ncbi.nlm.nih.gov/36534356/)

[Unknown, BIIB080 Phase 1/2 in AD (n.d.)](https://pubmed.ncbi.nlm.nih.gov/37354457/)

Unknown, NIO752 clinical development (n.d.)

[Unknown, RNase H1 mechanism in ASO therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Unknown, ASO chemistry advances for CNS (2024)](https://pubmed.ncbi.nlm.nih.gov/38456712/)

[Unknown, Tau isoform regulation by ASOs (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)